Brought to you by 
Third Rock puts $40mm into Blueprint Medicines’ Series A
25 May 2012
Executive Summary
Personalized cancer therapy start-up Blueprint Medicines has raised $40mm in Series A funding from sole investor Third Rock Ventures, which has also been incubating the company since the beginning of 2011.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Third Rock puts $40mm into Blueprint Medicines’ Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice